PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Dhiraj Yadav; Walter G. Park; Evan L. Fogel; Liang Li; Suresh T. Chari; Ziding Feng; William E. Fisher; Christopher E. Forsmark; Christie Y. Jeon; Aida Habtezion; Phil A. Hart; Steven J. Hughes; Mohamed O. Othman; Jo Ann S. Rinaudo; Stephen J. Pandol; Temel Tirkes; Jose Serrano; Sudhir Srivastava; Stephen K. Van Den Eeden; David C. Whitcomb; Mark Topazian; Darwin L. Conwell

doi:10.1097/MPA.0000000000001170

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Dhiraj Yadav, Walter G. Park, Evan L. Fogel, Liang Li, Suresh T. Chari, Ziding Feng, William E. Fisher, Christopher E. Forsmark, Christie Y. Jeon, Aida Habtezion, Phil A. Hart, Steven J. Hughes, Mohamed O. Othman, Jo Ann S. Rinaudo, Stephen J. Pandol, Temel Tirkes, Jose Serrano, Sudhir Srivastava, Stephen K. Van Den Eeden, David C. WhitcombMark Topazian, Darwin L. Conwell

Internal Medicine

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

Original language	English
Pages (from-to)	1229-1238
Number of pages	10
Journal	Pancreas
Volume	47
Issue number	10
DOIs	https://doi.org/10.1097/MPA.0000000000001170
State	Published - Nov 1 2018

Bibliographical note

Funding Information:
PROCEED is part of the CPDPC, a cooperative agreement grant funded by the NCI (National Cancer Institute) and the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The participating sites, organizational structure of the CPDPC, and its studies are provided elsewhere in this issue of the journal29 and at http://cpdpc.mdanderson.org.

Funding Information:
‡‡‡Division of Research, Kaiser Permanente Northern California, Oakland, CA; §§§Departments of Cell Biology and Physiology; and ||||||Human Genetics, University of Pittsburgh, UPMC, Pittsburgh, PA. Received for publication July 21, 2018; accepted August 24, 2018. Address correspondence to: Dhiraj Yadav, MD, MPH, Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, 200 Lothrop St, M2, C-wing, Pittsburgh, PA 15213 (e‐mail: yadavd@upmc.edu). This study was supported by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers: U01DK108288 (S.T.C., M.T.), U01DK108300 (W.G.P., A.H.), U01DK108306 (D.C.W., D.Y.), U01DK108314 (C.Y.J., S.J.P.), UO1DK108300 (C.E.F., S.J.H.), U01DK108323 (E.L.F., T.T.), U01DK108326 (W.E.F., M.O.O.), U01DK108327 (P.H., D.L.C.), and U01DK108328 (Z.F., L.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.C.W. is a consultant for AbbVie, Regeneron, and Ariel Precision Medicine, and may have equity in Ariel Precision Medicine. The other authors declare no conflict. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001170

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

alcohol
biorepository
cohort
genetic
pancreas
tobacco

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Hepatology
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MPA.0000000000001170

Fingerprint

Dive into the research topics of 'PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer'. Together they form a unique fingerprint.

Cite this

Yadav, D., Park, W. G., Fogel, E. L., Li, L., Chari, S. T., Feng, Z., Fisher, W. E., Forsmark, C. E., Jeon, C. Y., Habtezion, A., Hart, P. A., Hughes, S. J., Othman, M. O., Rinaudo, J. A. S., Pandol, S. J., Tirkes, T., Serrano, J., Srivastava, S., Van Den Eeden, S. K., ... Conwell, D. L. (2018). PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. Pancreas, 47(10), 1229-1238. https://doi.org/10.1097/MPA.0000000000001170

@article{38c36284c2174fa890a1d5b162d83a37,

title = "PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer",

abstract = "Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.",

keywords = "alcohol, biorepository, cohort, genetic, pancreas, tobacco",

author = "Dhiraj Yadav and Park, {Walter G.} and Fogel, {Evan L.} and Liang Li and Chari, {Suresh T.} and Ziding Feng and Fisher, {William E.} and Forsmark, {Christopher E.} and Jeon, {Christie Y.} and Aida Habtezion and Hart, {Phil A.} and Hughes, {Steven J.} and Othman, {Mohamed O.} and Rinaudo, {Jo Ann S.} and Pandol, {Stephen J.} and Temel Tirkes and Jose Serrano and Sudhir Srivastava and {Van Den Eeden}, {Stephen K.} and Whitcomb, {David C.} and Mark Topazian and Conwell, {Darwin L.}",

note = "Funding Information: PROCEED is part of the CPDPC, a cooperative agreement grant funded by the NCI (National Cancer Institute) and the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The participating sites, organizational structure of the CPDPC, and its studies are provided elsewhere in this issue of the journal29 and at http://cpdpc.mdanderson.org. Funding Information: ‡‡‡Division of Research, Kaiser Permanente Northern California, Oakland, CA; §§§Departments of Cell Biology and Physiology; and ||||||Human Genetics, University of Pittsburgh, UPMC, Pittsburgh, PA. Received for publication July 21, 2018; accepted August 24, 2018. Address correspondence to: Dhiraj Yadav, MD, MPH, Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, 200 Lothrop St, M2, C-wing, Pittsburgh, PA 15213 (e‐mail: yadavd@upmc.edu). This study was supported by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers: U01DK108288 (S.T.C., M.T.), U01DK108300 (W.G.P., A.H.), U01DK108306 (D.C.W., D.Y.), U01DK108314 (C.Y.J., S.J.P.), UO1DK108300 (C.E.F., S.J.H.), U01DK108323 (E.L.F., T.T.), U01DK108326 (W.E.F., M.O.O.), U01DK108327 (P.H., D.L.C.), and U01DK108328 (Z.F., L.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.C.W. is a consultant for AbbVie, Regeneron, and Ariel Precision Medicine, and may have equity in Ariel Precision Medicine. The other authors declare no conflict. Copyright {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001170 Publisher Copyright: {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2018",

month = nov,

day = "1",

doi = "10.1097/MPA.0000000000001170",

language = "English",

volume = "47",

pages = "1229--1238",

number = "10",

}

Yadav, D, Park, WG, Fogel, EL, Li, L, Chari, ST, Feng, Z, Fisher, WE, Forsmark, CE, Jeon, CY, Habtezion, A, Hart, PA, Hughes, SJ, Othman, MO, Rinaudo, JAS, Pandol, SJ, Tirkes, T, Serrano, J, Srivastava, S, Van Den Eeden, SK, Whitcomb, DC, Topazian, M & Conwell, DL 2018, 'PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer', Pancreas, vol. 47, no. 10, pp. 1229-1238. https://doi.org/10.1097/MPA.0000000000001170

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies : Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. / Yadav, Dhiraj; Park, Walter G.; Fogel, Evan L. et al.

In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1229-1238.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies

T2 - Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

AU - Yadav, Dhiraj

AU - Park, Walter G.

AU - Fogel, Evan L.

AU - Li, Liang

AU - Chari, Suresh T.

AU - Feng, Ziding

AU - Fisher, William E.

AU - Forsmark, Christopher E.

AU - Jeon, Christie Y.

AU - Habtezion, Aida

AU - Hart, Phil A.

AU - Hughes, Steven J.

AU - Othman, Mohamed O.

AU - Rinaudo, Jo Ann S.

AU - Pandol, Stephen J.

AU - Tirkes, Temel

AU - Serrano, Jose

AU - Srivastava, Sudhir

AU - Van Den Eeden, Stephen K.

AU - Whitcomb, David C.

AU - Topazian, Mark

AU - Conwell, Darwin L.

N1 - Funding Information: PROCEED is part of the CPDPC, a cooperative agreement grant funded by the NCI (National Cancer Institute) and the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The participating sites, organizational structure of the CPDPC, and its studies are provided elsewhere in this issue of the journal29 and at http://cpdpc.mdanderson.org. Funding Information: ‡‡‡Division of Research, Kaiser Permanente Northern California, Oakland, CA; §§§Departments of Cell Biology and Physiology; and ||||||Human Genetics, University of Pittsburgh, UPMC, Pittsburgh, PA. Received for publication July 21, 2018; accepted August 24, 2018. Address correspondence to: Dhiraj Yadav, MD, MPH, Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, 200 Lothrop St, M2, C-wing, Pittsburgh, PA 15213 (e‐mail: yadavd@upmc.edu). This study was supported by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers: U01DK108288 (S.T.C., M.T.), U01DK108300 (W.G.P., A.H.), U01DK108306 (D.C.W., D.Y.), U01DK108314 (C.Y.J., S.J.P.), UO1DK108300 (C.E.F., S.J.H.), U01DK108323 (E.L.F., T.T.), U01DK108326 (W.E.F., M.O.O.), U01DK108327 (P.H., D.L.C.), and U01DK108328 (Z.F., L.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.C.W. is a consultant for AbbVie, Regeneron, and Ariel Precision Medicine, and may have equity in Ariel Precision Medicine. The other authors declare no conflict. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001170 Publisher Copyright: © 2018 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

AB - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

KW - alcohol

KW - biorepository

KW - cohort

KW - genetic

KW - pancreas

KW - tobacco

UR - http://www.scopus.com/inward/record.url?scp=85055078667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055078667&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001170

DO - 10.1097/MPA.0000000000001170

M3 - Article

C2 - 30325862

AN - SCOPUS:85055078667

VL - 47

SP - 1229

EP - 1238

IS - 10

ER -

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this